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IgG4-relateddiseaseisanewdiseaseclassiﬁcationestablishedinJapaninthe21stcentury.PatientswithIgG4-relateddiseasedisplay
hyper-IgG4-gammaglobulinemia, massive inﬁltration of IgG4+ plasma cells into tissue, and good response to glucocorticoids.
SinceIgG4overexpressionisalsoobservedinotherdisorders,itisnecessarytodiagnoseIgG4-relateddiseasecarefullyandcorrectly.
We therefore sought to determine cutoﬀ values for serum IgG4 and IgG4/IgG and for IgG4+/IgG+ plasma cells in tissue diagnostic
of IgG4-related disease. Patients and Methods. We retrospectively analyzed serum IgG4 concentrations and IgG4/IgG ratio and
IgG4+/IgG+ plasma cell ratio in tissues of 132 patients with IgG4-related disease and 48 patients with other disorders. Result.
Serum IgG4 >135 mg/dl demonstrated a sensitivity of 97.0% and a speciﬁcity of 79.6% in diagnosing IgG4-related disease, and
serum IgG4/IgG ratios >8% had a sensitivity and speciﬁcity of 95.5% and 87.5%, respectively. IgG4+cell/IgG+ cell ratio in tissues
>40% had a sensitivity and speciﬁcity of 94.4% and 85.7%, respectively. However, the number of IgG4+ cells was reduced in
severely ﬁbrotic parts of tissues. Conclusion. Although a recent unanimous consensus of all relevant researchers in Japan recently
established the diagnostic criteria for IgG4-related disease, ﬁndings such as ours indicate that further discussion is needed.2 International Journal of Rheumatology
1.Introduction
IgG4-related disease (IgG4-RD), a new disease classiﬁcation
ﬁrst established in Japan in the 21st century, is characterized
by hyper-IgG4-gammaglobulinemia and massive inﬁltration
of IgG4-positive plasma cells into various swollen organs
[1–10]. In general, a serum IgG4 concentration >135mg/dL
has been established as the cutoﬀ value for the diagnosis of
patients with IgG4-RD and is used in the joint consensus
criteria of the Okazaki and Umehara groups investigating
IgG4-RD for the Ministry of Health, Labor, and Welfare of
Japan [11].
Some patients with early or limited stage IgG4-RD, how-
ever, may show the suﬃcient pathological characteristics and
clinical features of this disease, such as good response to
glucocorticoids, despite having serum IgG4 concentrations
<135mg/dL. In addition, an IgG4+/IgG+ ratio >40% in
tissue and >10 cells/high-power ﬁeld (HPF) have been used
in the histopathologic diagnosis of IgG4-RD in Japan. Thus,
a proper diagnosis of these patients may require the use of
other criteria, including IgG4+/IgG plasma cell ratio. Since
lower cutoﬀ values may increase sensitivity while decreasing
speciﬁcity, it is necessary to establish accurate cut oﬀ values
for this ratio.
To better establish the diagnostic criteria for IgG4-RD,
we, the members of the IgG4+MOLPS/Mikulicz’s disease re-
search group in Japan, sought to determine the cutoﬀ values
for serum IgG4 and IgG4/IgG and for IgG4+/IgG+ plasma
cells in tissue diagnostic of IgG4-RD using retrospectively
collected data.
2.MaterialsandMethods
2.1. Measurement of Serum IgG4 Concentration. Serum IgG4
concentrations and IgG4/IgG ratio and the ratio of IgG4+/
IgG+ plasma cells in tissue were determined in 132 patients
with IgG4-RD and 48 patients with other disorders regis-
tered retrospectively in the IgG4+MOLPS/Mikulicz’s disease
research group (Table 1). The 48 patients with other disor-
ders included 33 with Sj¨ ogren’s syndrome, 3 with multicen-
tric Castleman’s disease (MCD), 3 with B-cell lymphoma, 2
with sarcoidosis, and 1 each with Kimura’s disease, ulcerative
colitis, autoimmune hepatitis, IgG-type monoclonal gam-
mopathy of undetermined signiﬁcance, progressive trans-
formation of the germinal center, scleritis, and severe kera-
toconjunctivitis sicca. The study was approved by the
review boards of Kanazawa Medical University and all other
collaborating institutions, and all patients provided written
informed consent for the use of their data and samples.
The sensitivities, speciﬁcities, and ROC curves of serum
IgG4 >135mg/dL and various serum IgG4/IgG ratios were
statistically analyzed using SPSS v.11 (SPSS Inc., Chicago, IL,
USA).
Patients with borderline IgG4-RD were deﬁned carefully
as those with (1) >40% IgG4+/IgG+ plasma cells in tissue,
(2) strict pathological diﬀerential, and (3) a typical clinical
Table 1: Involved organs in 132 patients with IgG4-RD. More than
half (64 cases) the patients in our series had so-called Mikulicz’s
disease, with symmetrical swelling of at least two sets of lacrimal,
parotid, or submandibular glands.
Involved organ Number of patients
Total 132
Lacrimal gland 75
Parotid gland 32
Submandibular gland 74
Pancreas 20
Kidney 21
Lung 6
Lymph node 4
Thyroid 4
Liver 3
Retroperitoneum 3
Dura 1
Hypophysis 1
Bile duct 1
course (spontaneous regression or no change without treat-
ment, or good response to an initial daily dose of <0.6mg/kg
prednisolone).
2.2. Analysis of IgG4+ Cells in Tissue. The numbers of IgG4+
and IgG+ cells in tissue samples from 36 patients with IgG4-
RD and from 21 with other disorders were determined by
counting cells counts in 5 high-power ﬁelds (HPF) under
light microscopy. We also recounted cell areas of 17 samples
frompatients with IgG4-RD that contained both ﬁbrotic and
nonﬁbrotic parts.
We also assessed the sensitivity and speciﬁcity of IgG4+/
IgG+ cell ratios >10%, >20%, >30%, >40%, and >50%,
and of >10, >20, >30, >40 and >50 IgG4+cells/HPF, as well
as the presence of obliterative phlebitis, storiform ﬁbrosis,
eosinophilia, ﬁbrosis, and lymphocyte inﬁltration as deter-
mined by hematoxylin and eosin staining in the diagnosis of
IgG4-RD.
Tissue samples with borderline IgG4-RD were deﬁned
as those with (1) serum IgG4 >135mg/dL, (2) strict patho-
logical diﬀerential, and (3) typical clinical course. Clinical
course including response to steroid is not included in the
comprehensive diagnostic criteria for IgG4-RD, to avoid the
needless treatment with steroid of patients suspected of hav-
ing IgG4-RD. As this was a retrospective analysis, however,
we analyzed the clinical course of these borderline patients,
including their response to steroid treatment.
3. Results
3.1. Serum IgG4 Concentration. As e r u mI g G 4c u t o ﬀ value
>135mg/dL had a sensitivity of 97.0% and a speciﬁcity of
79.6% for the diagnosis of IgG4-RD. In 4 patients with
relatively small and restricted lesions, however, this criterion
was not adequate to diagnose IgG4-RD, although all had aInternational Journal of Rheumatology 3
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Figure 1: ROC curves of absolute serum IgG4 concentration
(green) and serum IgG4/IgG ratio (blue). The two curves were
almost identical.
histopathology and clinical course compatible with IgG4-RD
(Table 2). All 4 patients were diagnosed with IgG4-RD based
on a serum IgG4/IgG ratio >8%.
In contrast, neither a serum IgG4 cutoﬀ of >135mg/dL
nor a serum IgG4/IgG ratio >8% was adequate for the diag-
nosis of four patients with MCD and one each with B-
cell lymphoma, scleritis, and Sj¨ ogren’s syndrome, because
all of these patients had hyper-IgG4-globulinemia associ-
ated with polyclonal gammopathy. We therefore estimated
the sensitivity and speciﬁcity of various IgG4/IgG ratios
(Table 3). We found that the ROC curves for absolute serum
IgG4 concentration and serum IgG4/IgG ratio were almost
identical (Figure 1).
3.2. Analysis of IgG4+ Cells in Tissue Samples. We also as-
sessed the ability of the ratio of IgG4+/IgG+ plasma cell
ratios in 5 HPFs of tissue samples to diagnose IgG4-RD. We
found that a ratio >40% had a sensitivity of 94.4% and a
speciﬁcity of 85.7% (Table 4). Although >10 IgG4+ cells per
HPF had a sensitivity of 100%, They had speciﬁcities of only
38.1%.
In tissues containing both ﬁbrotic and nonﬁbrotic areas,
we counting the number cells in each part showed that
ﬁbrotic areas contained fewer IgG4+ cells (Table 5).
We also assessed the ability of obliterative phlebitis and
storiform ﬁbrosis to diagnose IgG4-RD. Although both had
speciﬁcities of 100%, their sensitivities were not very high
(Table 4).
Table 2: Serum IgG and IgG4 concentrations and IgG4/IgG4 ratio
of patients with false-positive and false-negative diagnoses of IgG4-
RD.
False positives
Diagnosis IgG
(mg/dL)
IgG4
(mg/dL) IgG4/IgG
(1) MCD 7,080 4,560 64.4%
(2) MCD 4,420 690 15.6%
(3) B-cell lymphoma 2,510 456 18.2%
(4) MCD 2,960 295 10.0%
(5) MCD 2,476 295 11.9%
(6) B-cell lymphoma 4,010 271 6.8%
(7) Scleritis 2,900 232 8.0%
(8) Sarcoidosis 1,380 189 13.7%
(9) Sj¨ ogren’s syndrome 3,920 171 4.4%
(10) Malignant lymphoma 1,930 141 7.3%
False negatives
Diagnosis IgG(mg/dL) IgG4(mg/dL) IgG4/IgG
(1) IgG4-RD 1,149 125 10.9%
(2) IgG4-RD 1,210 123 10.2%
(3) IgG4-RD 1,228 111 9.0%
(4) IgG4-RD 1,260 106 8.4%
IgG4-RD: IgG4-related disease; MCD: multicentric Castleman’s disease.
Table 3: Sensitivity and speciﬁcity of serum cutoﬀ values in the
diagnosis of IgG4-RD.
Sensitivity Speciﬁcity
IgG4 > 135mg/dL 97.0% 79.6%
IgG4/IgG > 5% 99.2% 83.3%
IgG4/IgG > 6% 97.0% 83.3%
IgG4/IgG > 7% 97.0% 85.4%
IgG4/IgG > 8% 95.5% 87.5%
IgG4/IgG > 9% 92.4% 89.6%
IgG4/IgG > 10% 89.4% 91.7%
4. Discussion
SerumIgG4 >135mg/dL has been widelyaccepted asa cutoﬀ
value for diagnosis of IgG4-RD. Although this concentration
was determined by comparing patients with IgG4-related
sclerosing pancreatitis and those with pancreatic cancer [1],
it has also been used to diagnose IgG4-RD involving other
organs. For example, we have utilized this cutoﬀ value as
a diagnostic criterion for IgG4-related Mikulicz’s disease
[5] and IgG4-related kidney disease [12], and, in 2011,
it was adopted in the comprehensive clinical diagnostic
criteria of IgG4-related diseases [11]. Most patients with
IgG4-RD show multiple organ involvement at diagnosis,
with both high absolute serum IgG4 concentrations and
serum IgG4/IgG ratios. However, some patients with early
and/or limited stage IgG4-RD do not present with high
IgG4-globulinemia (Figure 2), with some not having IgG4
concentrations >135mg/dL. We have therefore tested the4 International Journal of Rheumatology
Table 4: Sensitivity and speciﬁcity of pathological ﬁndings for the
diagnosis of IgG4-RD.
Sensitivity Speciﬁcity
IgG4+/IgG+ > 10% 100.0% 33.3%
IgG4+/IgG+ > 20% 100.0% 47.6%
IgG4+/IgG+ > 30% 100.0% 71.4%
IgG4+/IgG+ > 40% 94.4% 85.7%
IgG4+/IgG+ > 50% 94.4% 95.2%
IgG4+cells/HPF > 10 100.0% 38.1%
IgG4+cells/HPF > 20 97.2% 42.9%
IgG4+cells/HPF > 30 97.2% 61.9%
IgG4+cells/HPF > 40 91.7% 66.7%
IgG4+cells/HPF > 50 86.1% 71.4%
Obliterative phlebitis 54.5% 100.0%
Storiform ﬁbrosis 31.4% 100.0%
Eosinophilia 42.9% 100.0%
Fibrosis 91.4% 82.4%
Lymphocytic
inﬁltration 100.0% 16.7%
Table 5: Recounting in each areas of 17 samples containing both
ﬁbrotic and nonﬁbrotic parts. All patients were diagnosed with
IgG4-RD but had biopsy specimens that were too small (samples
1–14) or with relatively large ﬁbrotic areas inadequate to diagnose
IgG4-RD (samples 15–17). All samples had >10 IgG4+ cells per
HPF.
Tissue Fibrosis+ Fibrosis−
(1) Pancreas 76.6% 94.0%
(2) Submandibular gland 75.4% 89.2%
(3) Submandibular gland 72.1% 73.0%
(4) Submandibular gland 72.1% 97.3%
(5) Submandibular gland 71.8% 99.1%
(6) Pancreas 67.7% 95.0%
(7) Labial salivary glands 65.0% 70.8%
(8) Lung 58.9% 94.4%
(9) Submandibular gland 49.2% 68.9%
(10) Gall bladder 48.6% 94.0%
(11) Bile duct 46.8% 95.0%
(12) Submandibular gland 46.2% 74.1%
(13) Orbit 44.2% 94.4%
(14) Submandibular gland 43.6% 95.0%
(15) Submandibular gland 33.3% 95.0%
(16) Submandibular gland 25.9% 51.5%
(17) Labial salivary glands 8.0% 76.2%
ability of alternative criteria to diagnose for IgG4-RD.
Although we found that a serum IgG4/IgG ratio >5% had
the highest sensitivity, the normal ratio is about 5-6%,
making this cut oﬀ value misleading. An IgG4/IgG ratio
>8% had a sensitivity similar to that of absolute IgG4
>135mg/dL, but a greaterspeciﬁcity, enabling us to diagnose
4 patients with lower absolute IgG4 concentrations as having
HE lgG lgG4
Figure 2: Histopathology of a patient with limited stage IgG4-
related dacryoadenitis. A 35-year-old woman presented with
swelling of her bilateral lacrimal glands. Her serum IgG and
IgG4concentrations were1,149mg/dLand125mg/dL,respectively,
and her serum IgG4/IgG ratio was 10.88%. Histopathological
examination of a lacrimal gland biopsy revealed IgG4+ plasma cell
inﬁltration, with an IgG4+/IgG+ cell ratio of 74.7%, and 53 IgG4+
cellsperHPF,althoughscleroticchangeswerenotsevere.Treatment
with prednisolone 20mg/day resulted in a rapid and dramatic
improvementinsymptoms.AlthoughusinganabsoluteserumIgG4
cutoﬀconcentrationof>135mgdidnotresultindiagnosisofIgG4-
RD, her clinical course and histopathology were typical of IgG4-
RD. However, using a serum IgG4/IgG ratio >8% as a cutoﬀ value
resulted in a diagnosis of IgG4-RD.
IgG4-RD (Table 2). Since the standard cut oﬀ of absolute
IgG4 >135mg/dL demonstrated excellent sensitivity and
speciﬁcity, it should be utilized, except for patients with early
and/or limited IgG4-RD, for whom we propose using an
IgG4/IgG ratio >8%.
Careful diagnosis is required in patients with lower
IgG4 concentrations, since those patients may have other
distinct disorders with diﬀerent clinical features than IgG4-
RD. Patients with untypical clinical courses, including gluco-
corticoid refractoriness, should be reassessed.
IgG4+/IgG+plasmacellratiosintissue>40%and>50%,
and >10 IgG4+ cells per HPF have been used for the
diagnosis of IgG4-RD. We found that an IgG4+/IgG+ cell
ratio >40% in tissue had a sensitivity of 94.4% and a
speciﬁcity of 85.7% in the diagnosis of IgG4-RD. We also
found that IgG4+ plasma cell concentrations in tissue were
diminished in ﬁbrotic tissue areas, suggesting that a ratio
>40% is a better histopathologic cutoﬀ value. The presence
of obliterative phlebitis and storiform ﬁbrosis demonstrated
speciﬁcities of 100%, but their sensitivities were much lower,
indicatingthattheseﬁndingswouldbeusefulwhenaddedto,
but not in place of, other results.
Since patients with disorders such as MCD and lym-
phoma may demonstrate hyper-IgG4-gammaglobulinemia
and massive IgG4+ plasma cell inﬁltration in tissue, serum
IgG4 concentration and IgG4+ cells in tissue are not speciﬁc
indicators of IgG4-RD. Rather, a diagnosis of IgG4-RD
should be based on the overall balance of clinical features,
such as disease distribution throughout the body, clinical
course, serum concentrations, and histopathology.
The pathologic consensus statement of the ﬁrst inter-
national Symposium on IgG4-RD in Boston did not adopt
IgG4+/IgG+ cell ratio in tissue as diagnostic, although itInternational Journal of Rheumatology 5
did suggest cutoﬀsf o rn u m b e r so fI g G 4 +c e l l si nH P F so f
various organs. This, however, may be confusing for many
pathologists and physicians. Although pathologic ﬁndings
are very important in the diagnosis for IgG4-RD, clinical
features and serological ﬁndings should be included.
Recently, some patients with IgG4-RD were found to
have lymphoma [13, 14] and other types of cancer [15, 16].
Thus IgG4-RD may not always be a benign disease with good
prognosis. Many patients referred to our centers with glu-
cocorticoid refractory IgG4-RD were diagnosed incorrectly,
suggesting the need for more accurate diagnostic criteria for
these diseases.
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